|
Video: What is a Stock Split?
|
|
Spectrum Pharmaceuticals is a commercial-stage biopharmaceutical company. Co. is engaged in acquiring, developing, and commercializing targeted oncology therapies. Co. has one commercial asset, ROLVEDON, which is a long-acting granulocyte colony-stimulating factor for the treatment of chemotherapy-induced neutropenia; as well as one drug candidate in late-stage development, Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations. According to our SPPI split history records, SPPI has had 0 splits. | |
|
SPPI (SPPI) has 0 splits in our SPPI split history database.
Looking at the SPPI split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SPPI shares, starting with a $10,000 purchase of SPPI, presented on a split-history-adjusted basis factoring in the complete SPPI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
08/01/2023 |
|
Start price/share: |
$6.91 |
|
End price/share: |
$1.03 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-85.09% |
|
Average Annual Total Return: |
-18.57% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,491.40 |
|
Years: |
9.26 |
|
|
|
|
|